Status:
COMPLETED
Pharmacokinetic Interaction Between DWP14012 and DWC202005 in Healthy Volunteers
Lead Sponsor:
Daewoong Pharmaceutical Co. LTD.
Conditions:
Drug-drug Interaction
Eligibility:
All Genders
19-50 years
Phase:
PHASE1
Brief Summary
An open-label, multiple-dose clinical trial to evaluate the safety/tolerability and pharmacokinetic interaction between DWP14012 and DWC202005 in healthy volunteers
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Healthy adults aged 19 to 50 years with BMI between 18.5 kg/m2 and 30.0 kg/m2
- Capable of understanding provided information and complying with protocol requirements
- Provide written informed consent to participate in the study
Exclusion
Key Trial Info
Start Date :
September 6 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 21 2020
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT04328766
Start Date
September 6 2020
End Date
November 21 2020
Last Update
August 16 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nucleus Network (QPharm)
Queensland, Queensland, Australia, 78